Keyword: Steve Miller

Bayer and its partner Loxo Oncology picked up FDA approval for their novel "tissue agnostic" TRK inhibitor Vitrakvi.

Gilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is on board.

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.

Amgen’s migraine drug, Aimovig, isn’t even approved by the FDA yet, but questions about its insurance coverage overshadowed some solid Q1 earnings.

In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.

Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.

Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.

A top official at Express Scripts said he’s seeing increased cooperation on pricing from the pharma industry.

How does Dupixent's list price square with Sanofi and Regeneron's vows for a fair cost? Pretty well, say analysts, number-crunchers and at least one payer that will foot the bill.

In response to tough new comments on pricing from a Gilead Sciences exec, Express Scripts is fighting back.